Search results for "Coronavirus"


 
Results 51 - 60 of about 177 for "Coronavirus".
Sort by: Relevance | Newest | Oldest

New research on booster doses, breakthrough infections, long-term COVID-19 symptoms

A vaccine booster significantly reduced risk of severe disease or death from COVID-19, full vaccination provided more protection than previous infection, many patients reporting persistent symptoms did not have antibodies to SARS-CoV-2, and a trial of outpatient treatment was ineffective, recent studies found.
https://immattersacp.org/weekly/archives/2021/11/09/1.htm
9 Nov 2021

Regulatory changes for COVID-19 vaccine; data on waning immunity, outpatient therapies

The FDA authorized vaccinating children, the NIH supported concurrent use of flu and COVID-19 shots, and the CDC addressed a fourth dose of COVID-19 vaccine for the immunocompromised. Trials found benefit from a new monoclonal antibody and an old antidepressant for high-risk outpatients.
https://immattersacp.org/weekly/archives/2021/11/02/1.htm
2 Nov 2021

More booster authorizations, research on vaccine safety and uptake

The FDA and CDC endorsed boosters of the Johnson & Johnson and Moderna vaccines. Recent research showed that COVID-19 vaccination was not associated with miscarriage, and a small financial incentive for receiving a COVID-19 vaccine or providing transportation to a vaccination site increased uptake.
https://immattersacp.org/weekly/archives/2021/10/26/1.htm
26 Oct 2021

Boosters, antithrombotic therapy, mental health effects, more COVID-19 news

FDA advisors recommended booster administration for the Moderna vaccine for certain populations, an ACP/Annals forum covered the immunology of SARS-CoV-2, a trial showed that neither aspirin nor apixaban benefited outpatients with COVID-19, and ACP partnered with YouTube to combat medical misinformation related to COVID-19.
https://immattersacp.org/weekly/archives/2021/10/19/2.htm
19 Oct 2021

Register now for next ACP, Annals of Internal Medicine forum on COVID-19

On Oct. 8, panelists will provide insight on the clinical implications of the immunology of SARS-CoV-2 and the COVID-19 vaccine, including the status of booster doses and the efficacy of vaccination in various groups.
https://immattersacp.org/weekly/archives/2021/10/05/2.htm
5 Oct 2021

Studies find monoclonal antibodies and remdesivir effective, while vaccine-associated myocarditis is rare

A trial of casirivimab plus imdevimab indicated it reduced risk of hospitalization or death, the CDC urged vaccination during pregnancy and updated its v-safe tool, and an analysis showed that postvaccine myocarditis occurred in men and resolved with conservative treatment.
https://immattersacp.org/weekly/archives/2021/10/05/1.htm
5 Oct 2021

CDC recommendations on COVID-19 vaccine boosters, new data on vaccine effectiveness

Several groups in the U.S. are now eligible to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after completing the initial two-dose series.
https://immattersacp.org/weekly/archives/2021/09/28/1.htm
28 Sep 2021

Research, regulators consider booster dose of COVID-19 vaccine

FDA advisors recommended boosters for older and high-risk patients. The latest COVID-19 research looked at vaccine effectiveness, remdesivir's effects, an early indicator of vaccine-induced immune thrombotic thrombocytopenia, and rates of follow-up after hospitalization.
https://immattersacp.org/weekly/archives/2021/09/21/1.htm
21 Sep 2021

Advice on monoclonal antibodies; new data on long-term COVID-19 symptoms, vaccine efficacy

The NIH offered guidance on prioritization when monoclonal antibodies can't be given to all eligible patients. Two studies looked at patients with persistent COVID-19 symptoms, and other research confirmed the safety and effectiveness of the vaccines, even with the delta variant.
https://immattersacp.org/weekly/archives/2021/09/14/2.htm
14 Sep 2021

New data on delta variant of COVID-19 and vaccines

Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
https://immattersacp.org/weekly/archives/2021/08/31/1.htm
31 Aug 2021

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next